Antibody response to influenza immunization in coronary artery disease patients: A controlled trial

Maryam Keshtkar-Jahromi, Hossein Vakili, Mohammad Rahnavardi, Sharareh Gholamin, Seyed Mostafa Razavi, Ali Eskandari, Roxana Sadeghi, Hossein Vatan-Pour, Marzieh Keshtkar-Jahromi, Babak Haghighat, Mohammad Ghaffaripour, Talat Mokhtari-Azad

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Safety of and humoral immune response to the anti-influenza vaccine in coronary artery disease (CAD) patients were evaluated. The trivalent vaccine was administered to 137 eligible CAD patients and 67 age- and sex-matched healthy individuals. Antibody (Ab) titers were measured before and 1 month after vaccination. CAD and HC groups were not significantly different in serologic response and magnitude of change in antibody titers against each of the vaccine antigens. In multivariate analyses, regular exercise and using multivitamin supplements were independently associated with better antibody response among CAD patients. There were no major cardiac or general adverse effects. Influenza vaccine was found safe in CAD patients and antibody responses were similar to HCs.

Original languageEnglish (US)
Pages (from-to)110-113
Number of pages4
Issue number1
StatePublished - Dec 10 2009
Externally publishedYes


  • Antibody
  • Coronary artery disease
  • Influenza vaccine
  • Serologic response

ASJC Scopus subject areas

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Antibody response to influenza immunization in coronary artery disease patients: A controlled trial'. Together they form a unique fingerprint.

Cite this